Nvidia CEO Jensen Huang discusses AI's future at GTC 2025
GTC 2025, heralded as 'AI Woodstock,' is being hosted at SAP Center in San Jose, Calif. Huang's keynote has been focused on the company's advancements in AI and his predictions for how the industry will move over the next few years.
Huang said demand for GPUs from the top four cloud service providers is surging, adding that he expects Nvidia's data center infrastructure revenue to hit $1 trillion by 2028. He also announced that U.S. car maker General Motors would integrate Nvidia technology in its new fleet of self-driving cars.
The Nvidia head also unveiled the company's Halos system, an AI solution built around automotive — especially autonomous driving — safety.
'We're the first company in the world, I believe, to have every line of code safety assessed,' Huang said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Nvidia CEO to hold media briefing in Beijing on July 16
By Che Pan and Mei Mei Chu BEIJING (Reuters) -Nvidia CEO Jensen Huang will hold a media briefing in Beijing on July 16, an official from the company said on Sunday, marking his second visit to the country after a trip in April where he stressed the importance of the Chinese market. Since 2022, the U.S. government has imposed restrictions on the export of Nvidia's most advanced chips to China, citing concerns over potential military applications. The U.S. also imposed a ban earlier this year on sales of Nvidia's H20 artificial intelligence chips to the country - which had been Nvidia's most powerful AI chip cleared for Chinese sales. Huang's latest visit has been closely-watched in both U.S. and China. A bipartisan pair of U.S. senators on Friday sent a letter to Huang about his China trip, asking him to abstain from meeting with companies that are working with military or intelligence bodies in the People's Republic of China. The senators also asked Huang to refrain from meeting with entities named on the United States' restricted export list. Nvidia has faced increased competition from Chinese tech giant Huawei and other makers of graphics processing units - the chips used to train artificial intelligence. But Chinese companies, including its big tech firms, still crave Nvidia chips due to the company's computing platform known as CUDA. China generated $17 billion in revenue for Nvidia in the fiscal year ending January 26, accounting for 13% of the company's total sales, based on its latest annual report. Huang has consistently highlighted China as a critical market for Nvidia's growth. Nvidia's market value topped $4 trillion for the first time last week, solidifying the chipmaker's position as Wall Street's central player in a race to dominate AI technology. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
2 Technology Stocks That Could Go Parabolic
These two technology stocks are in red-hot form of late, and are set to deliver more upside going forward. Both are capable of sustaining their healthy growth momentum for a long time. Both are likely to outpace Wall Street's growth expectations as well. 10 stocks we like better than Nvidia › Technology stocks have made an impressive recovery in the past three months or so following a difficult start to the year when a variety of factors, including a tariff-induced trade war, lofty valuations, and the lack of interest rate cuts by the Federal Reserve this year, spooked some investors. The tech-laden Nasdaq Composite index has jumped a remarkable 21% in the space of just three months (although it's up just 7% year to date). This broad market rally explains why many technology names have also shot up big time of late, recording a parabolic increase in their stock prices. A parabolic move refers to a rapid increase in the stock price of a company in a short time, identical to the right side of a parabolic curve. Two tech stocks in particular have been crushing the market of late and have the potential to make another parabolic move thanks to their stunning growth profiles. Memory specialist Micron Technology's (NASDAQ: MU) stock spiked 58% in the past three months. But even after this recent surge, you can buy the chipmaker at an extremely attractive valuation since it is trading at just 22 times trailing earnings. The forward earnings multiple of just 10 is even more attractive. Given the strong forecasted growth rates for Micron, it has strong potential to be a no-brainer buy. Micron's revenue in the third quarter of fiscal 2025 (which ended on May 29) was up by 37% year over year to $9.3 billion. Its adjusted earnings grew by over 3x to $1.91 per share on the back of a massive jump in its margins. The memory chip manufacturer has received a big artificial intelligence (AI)-powered boost in recent quarters. AI accelerators from the likes of Nvidia (NASDAQ: NVDA), AMD, Broadcom, and Marvell Technology are packing in huge amounts of high-bandwidth memory (HBM) so that large amounts of data can be transmitted at terrific speeds in AI data centers. Market research provider Yole Group estimates that the HBM market's revenue could double in 2025, leading to a 17% jump in the overall memory market's revenue to $200 billion. Importantly, the booming demand for both compute and storage memory chips used in data centers and high-performance computing (HPC) could take the overall memory market's revenue to $302 billion in 2030, implying a 50% increase from this year's estimated revenue. Investors can capitalize on this lucrative incremental growth opportunity with Micron's help, as it controls 24% of the dynamic random-access memory (DRAM) market and around 12% of the NAND (short for NOT AND) flash storage market. The company also seems to be gaining ground in memory chips. Samsung, which is one of the top three players in this market along with SK Hynix and Micron itself, seems to be struggling for traction in HBM. As such, it is easy to see why Micron's earnings growth estimates have received a major boost of late. The company's improved earnings power and its cheap valuation suggest that its parabolic run has plenty left in the tank to keep going. The market could reward Micron with a premium multiple, considering its outstanding growth. After rising 43% in just three months, Nvidia is also on a parabolic run right now. However, Wall Street seems to be underestimating the company's growth potential -- and that's precisely why I believe that it can sustain its current rally going forward. When Nvidia released its fiscal 2026 first-quarter results (for the three months ended April 27, 2025) almost two months ago, it exceeded consensus expectations despite being hamstrung by restrictions on sales to Chinese customers. Nvidia's guidance was also ahead of expectations, even though it is on track to lose $8 billion in potential revenue due to export restrictions to China. Analysts expect Nvidia's revenue to increase by 53% in the current fiscal year to just under $200 billion. The company's top line jumped 69% year over year in fiscal Q1, and it won't be surprising to see it maintain that terrific momentum thanks to the new sales opportunities that are coming its way beyond China. Nvidia is gaining business for its AI chips around the globe. It partners with 18 telecom companies globally to build sovereign AI (i.e., government-funded) infrastructure on five continents. Nvidia reportedly sold $17 billion worth of chips to China in the previous fiscal year. Its push into sovereign AI could help it mitigate the loss of Chinese business, as Bank of America estimates that sovereign AI could unlock a $50 billion annual revenue opportunity for the company. Investment banking firm Oppenheimer, on the other hand, has a more ambitious forecast and expects the global sovereign AI market to generate a $1.5 trillion annual revenue opportunity. Given that Nvidia is reportedly involved in almost every deal for rolling out sovereign AI, as per Citi, investors would do well to look past the lost opportunity in China. There is a solid chance of Nvidia outpacing consensus estimates going forward, and that could give its parabolic rally a nice shot in the arm. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Bank of America is an advertising partner of Motley Fool Money. Citigroup is an advertising partner of Motley Fool Money. Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Bank of America, and Nvidia. The Motley Fool recommends Broadcom and Marvell Technology. The Motley Fool has a disclosure policy. 2 Technology Stocks That Could Go Parabolic was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
3 AI-Driven Medical Device Stocks to Watch in 2025
Globally, generative artificial intelligence (Gen AI) and agentic AI are increasingly being integrated into medical devices, transforming both clinical workflows and patient care. Gen AI is primarily being used for content creation and design optimization within the medical device space. For instance, Gen AI models generate synthetic medical images like magnetic resonance imaging (MRI), computed tomography (CT) and X-rays to train diagnostic tools and augment datasets. NVIDIA NVDA cofounded the Medical Open Network for AI ('MONAI') with the world's leading academic medical centers to establish an inclusive community of AI researchers, developing and exchanging best practices for AI in healthcare imaging across academia and enterprise researchers. Additionally, Gen AI powers real-time clinical documentation tools embedded within diagnostic devices, such as Nuance Communications's Dragon Ambient eXperience ('DAX'). These devices transcribe doctor-patient conversations into structured clinical notes, minimizing administrative burden and enhancing documentation accuracy. Alternatively, agentic AI enables medical devices to act autonomously and make decisions based on real-time data. Agentic AI also supports predictive maintenance in connected medical equipment, such as MRIs and ventilators. This enables fault detection and automated service scheduling, thereby reducing equipment downtime. In the surgical field, AI-guided robotic systems, such as Intuitive Surgical's ISRG da Vinci platform, are integrating agentic AI features to assist with real-time tissue navigation and instrument movement. Here, we have picked three medical devices stocks, namely Boston Scientific Corporation BSX, Johnson & Johnson JNJ and GE HealthCare Technologies Inc. GEHC, which are likely to perform well in 2025, driven by strong AI adoption. Rising Demand for Precision and Personalized Medicine: AI enables medical devices to deliver highly individualized diagnostics and treatments. For instance, AI algorithms can analyze patient-specific imaging data or genetic profiles to guide the design of implants, surgical plans, or therapeutic regimens, improving patient outcomes. Favorable Regulatory Environment: Regulatory oversight for AI in the United States falls under the FDA's Software as a Medical Device (SaMD) segment. Over 700 AI-enabled devices have been approved, which is more than 10 times the number available in 2020. In January, the FDA released a draft guidance on adaptive AI systems, which have reduced uncertainty for developers, encouraging innovation and faster approvals. Boston Scientific is a major manufacturer of interventional medical devices. The company has been investing in AI to support its devices and improve procedural outcomes. It's HeartLogic is a heart failure diagnostic that utilizes AI to detect worsening heart failure in patients with implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds). The Rhythm AI module in the Rhythmia HDx mapping system can automatically interpret electroanatomical maps to identify arrhythmia circuits, enabling electrophysiologists to target ablation therapy more effectively. Meanwhile, the company's Coronary Advanced Analysis software uses AI to analyze optical coherence tomography images to characterize plaque. Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has a projected 2025 sales growth rate of 16.4%, higher than the industry's flat growth. The company has a favorable current cashflow rate of 26.5% against the industry's -2.6%. For 2025, its earnings are expected to grow 15.9%. Boston Scientific Corporation price | Boston Scientific Corporation Quote Johnson & Johnson is a healthcare conglomerate with a major MedTech division (Johnson & Johnson MedTech) focused on medical devices and diagnostics. The company employs AI for surgical robotics, digital surgery analytics and imaging. It has developed an ecosystem called Ottava, its next-gen robotic surgery platform, and the Caresurgical/VELYS digital surgery systems, which use data and AI for procedure planning. Its Polyphonic Digital Ecosystem connects operating rooms, allowing surgeons to share live video and data with remote peers. AI in this system helps identify significant events in the surgery video feed for discussion. Johnson & Johnson, carrying a Zacks Rank #2 at present, has a historical earnings growth rate of 5.5%, higher than the industry's 2.8%. The company has a net margin of 24.4%, outperforming the industry's 18.6%. For 2025, its sales are expected to grow 2.8%. Johnson & Johnson price | Johnson & Johnson Quote GE HealthCare is a global leader in medical imaging, diagnostics and healthcare. AI is central to the company's digital strategy, which focuses on its precision care framework. In 2023, it topped the FDA list of AI-enabled medical devices with 80 listed 510(k) clearances or authorizations to date in the United States. Recently, the company has launched CleaRecon DL — an AI-driven solution that enhances cone-beam computed tomography image quality. Also, its Invenia Automated Breast Ultrasound Premium, the latest 3D ultrasound, offers advanced AI and innovative features to drive faster, reproducible supplemental screening and streamline exam readings on patients with dense breasts. GE HealthCare, carrying a Zacks Rank #3 (Hold) at present, has a projected 2025 sales growth rate of 3.2%, higher than the industry's flat growth. The company has a favorable current cashflow rate of 9.7% against the industry's -2.6%. GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
